<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03595488</url>
  </required_header>
  <id_info>
    <org_study_id>1828-A-18</org_study_id>
    <nct_id>NCT03595488</nct_id>
  </id_info>
  <brief_title>Dupilumab for Aspirin-exacerbated Respiratory Disease</brief_title>
  <official_title>Dupilumab as add-on Therapy for Aspirin-exacerbated Respiratory Disease (AERD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rochester General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rochester General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects with physician-diagnosed aspirin-exacerbated respiratory disease (AERD) who remain
      unacceptably symptomatic with a SNOT 22 score &gt; 18 despite routine medical therapy will be
      enrolled in this single center, single-blinded study assessing the efficacy of dupilumab in
      AERD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single blind, placebo controlled trial to be conducted in adult patients with AERD
      to determine the efficacy and safety of dupilumab in treating symptoms of chronic
      rhinosinusitis.

      All subjects will be treated with the FDA-approved and the commercially available dose for
      adult atopic dermatitis of 300 mg every 2 weeks administered subcutaneously, based on the
      observed efficacy and safety of this dose. In addition to atopic dermatitis, this dose has
      also been shown to be efficacious in adult asthma.15 Patients will not be treated with a
      loading dose since other studies of dupilumab in asthma and chronic rhinosinusitis with nasal
      polyposis have not used a loading dose.

      There will be a one month screening period to determine the patient's eligibility and
      establish symptom control and baseline parameters.

      Patients will continue their background medications for chronic rhinosinusitis with nasal
      polyposis and asthma. These medications may include nasal corticosteroids, nasal
      antihistamines, systemic antihistamines, leukotriene receptor antagonists, 5 lipo-oxygenase
      inhibitors, inhaled corticosteroids, long-acting beta agonists, and long acting muscarinic
      antagonists. These controller medications will not be dispensed or supplied by the sponsor.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 5, 2018</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SNOT 22 Score</measure>
    <time_frame>From baseline to completion of study(7 months total)</time_frame>
    <description>This is a patient-reported outcome score for chronic rhinosinusitis with or without nasal polyposis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>UPSIT</measure>
    <time_frame>From baseline to completion of study( 7 months total)</time_frame>
    <description>Univ. of Pennsylvania smell identification test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lund Mackay score</measure>
    <time_frame>From baseline to completion of study( 7 months total)</time_frame>
    <description>Objective score for CT sinus imaging, this is a widely used method for radiologic staging of chronic rhinosinusitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACT score</measure>
    <time_frame>From baseline to completion of study( 7 months total)</time_frame>
    <description>Validated asthma control test, a series of 5 questions related to patient's asthma control over the previous 4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Mini-AQLQ, 15 questions to assess quality of life. This assessment takes approximately 4-5 minutes to complete the questions.</measure>
    <time_frame>From baseline to completion of study( 7 months total)</time_frame>
    <description>Validated asthma quality of life score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1</measure>
    <time_frame>From baseline to completion of study( 7 months total)</time_frame>
    <description>Forced expiratory volume in first second from spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FeNO</measure>
    <time_frame>From baseline to completion of study( 7 months total)</time_frame>
    <description>Exhaled nitric oxide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophil count</measure>
    <time_frame>From baseline to completion of study( 7 months total)</time_frame>
    <description>Absolute eosinophil count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total serum IgE</measure>
    <time_frame>From baseline to completion of study( 7 months total)</time_frame>
    <description>Total IgE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum tryptase</measure>
    <time_frame>From baseline to completion of study( 7 months total)</time_frame>
    <description>Biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum TARC (thymus and activation regulated cytokine)</measure>
    <time_frame>From baseline to completion of study( 7 months total)</time_frame>
    <description>Biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum prostaglandin D2</measure>
    <time_frame>From baseline to completion of study( 7 months total)</time_frame>
    <description>Biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour urinary leukotriene E4</measure>
    <time_frame>From baseline to completion of study( 7 months total)</time_frame>
    <description>Biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of dupilumab</measure>
    <time_frame>From baseline to completion of study( 7 months total)</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess cumulative dose of systemic steroids</measure>
    <time_frame>From baseline to completion of study( 7 months total)</time_frame>
    <description>Impact on systemic steroids</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Aspirin-exacerbated Respiratory Disease</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-blinded, Dupilumab or matching placebo will be administered to the patients at the study visits. At each study visit, a single dose of dupilumab or placebo will be dispensed to the patients to be administered at home.
300 mg/2 ml solution in a single-dose pre-filled syringe with needle shield given once every 2 weeks in a subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab</intervention_name>
    <description>dupilumab 300 mg subcutaneous injection every 2 weeks</description>
    <arm_group_label>Treatment arm</arm_group_label>
    <other_name>Matching placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 18 years and older with a physician diagnosis of aspirin-exacerbated
             respiratory disease, as defined by a physician diagnosis of asthma, chronic
             rhinosinusitis with nasal polyposis, and a convincing clinical history of NSAID
             sensitivity

          2. All subjects must have a SNOT 22 score ≥ 19 despite standard medical therapy. This
             minimal SNOT 22 was calculated by taking the range of SNOT 22 scores in studies of
             normal controls plus 8.9, which is the minimal clinically meaningful improvement in
             SNOT 22 score detected by patients.

          3. Able to understand and willingness to sign informed consent

          4. Able to comply with study procedures

        Exclusion Criteria:

          1. Patient &lt; 18 years of age

          2. Pregnancy or breast feeding

          3. Current tobacco use

          4. Significant, uncontrolled medical conditions

          5. Ongoing malignancy or history of malignancy in remission within the past 12 months

          6. Current treatment with immunosuppressive medications except chronic oral steroids

          7. Currently increasing dose of aeroallergen immunotherapy (patients on stable dose of
             aeroallergen immunotherapy will be allowed to participate)

          8. Treatment with omalizumab, reslizumab, mepolizumab within 4 months of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S Shahzad Mustafa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lead Physician</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rochester Regional Health - Allergy/Immunology</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol. 2015 Mar;135(3):676-81.e1. doi: 10.1016/j.jaci.2014.08.020. Epub 2014 Oct 3.</citation>
    <PMID>25282015</PMID>
  </reference>
  <reference>
    <citation>Mullol J, Picado C. Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2013 May;33(2):163-76. doi: 10.1016/j.iac.2012.11.002. Epub 2012 Dec 23. Review. Erratum in: Immunol Allergy Clin North Am. 2013 Aug;33(3):xi.</citation>
    <PMID>23639706</PMID>
  </reference>
  <reference>
    <citation>Ta V, White AA. Survey-Defined Patient Experiences With Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract. 2015 Sep-Oct;3(5):711-8. doi: 10.1016/j.jaip.2015.03.001. Epub 2015 Apr 7.</citation>
    <PMID>25858054</PMID>
  </reference>
  <reference>
    <citation>Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2003 Jan;111(1):180-6.</citation>
    <PMID>12532116</PMID>
  </reference>
  <reference>
    <citation>Stevenson DD, Pleskow WW, Simon RA, Mathison DA, Lumry WR, Schatz M, Zeiger RS. Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol. 1984 Apr;73(4):500-7.</citation>
    <PMID>6368649</PMID>
  </reference>
  <reference>
    <citation>Świerczyńska-Krępa M, Sanak M, Bochenek G, Stręk P, Ćmiel A, Gielicz A, Plutecka H, Szczeklik A, Niżankowska-Mogilnicka E. Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. J Allergy Clin Immunol. 2014 Oct;134(4):883-90. doi: 10.1016/j.jaci.2014.02.041. Epub 2014 Apr 24.</citation>
    <PMID>24767875</PMID>
  </reference>
  <reference>
    <citation>Fruth K, Pogorzelski B, Schmidtmann I, Springer J, Fennan N, Fraessdorf N, Boessert A, Schaefer D, Gosepath J, Mann WJ. Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease. Allergy. 2013;68(5):659-65. doi: 10.1111/all.12131. Epub 2013 Mar 7.</citation>
    <PMID>23464577</PMID>
  </reference>
  <reference>
    <citation>Esmaeilzadeh H, Nabavi M, Aryan Z, Arshi S, Bemanian MH, Fallahpour M, Mortazavi N. Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial. Clin Immunol. 2015 Oct;160(2):349-57. doi: 10.1016/j.clim.2015.05.012. Epub 2015 Jun 14.</citation>
    <PMID>26083948</PMID>
  </reference>
  <reference>
    <citation>Waldram JD, White AA. A survey of aspirin desensitization practices among allergists and fellows in training in the United States. J Allergy Clin Immunol Pract. 2016 Nov - Dec;4(6):1253-1255. doi: 10.1016/j.jaip.2016.06.016. Epub 2016 Jul 21.</citation>
    <PMID>27452889</PMID>
  </reference>
  <reference>
    <citation>Samuelsson B, Dahlén SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 1987 Sep 4;237(4819):1171-6. Review.</citation>
    <PMID>2820055</PMID>
  </reference>
  <reference>
    <citation>Laidlaw TM, Boyce JA. Aspirin-Exacerbated Respiratory Disease--New Prime Suspects. N Engl J Med. 2016 Feb 4;374(5):484-8. doi: 10.1056/NEJMcibr1514013.</citation>
    <PMID>26840139</PMID>
  </reference>
  <reference>
    <citation>Bachert C, Zhang N. Chronic rhinosinusitis and asthma: novel understanding of the role of IgE 'above atopy'. J Intern Med. 2012 Aug;272(2):133-43. doi: 10.1111/j.1365-2796.2012.02559.x. Review.</citation>
    <PMID>22640264</PMID>
  </reference>
  <reference>
    <citation>Patou J, Gevaert P, Van Zele T, Holtappels G, van Cauwenberge P, Bachert C. Staphylococcus aureus enterotoxin B, protein A, and lipoteichoic acid stimulations in nasal polyps. J Allergy Clin Immunol. 2008 Jan;121(1):110-5. Epub 2007 Nov 5.</citation>
    <PMID>17980412</PMID>
  </reference>
  <reference>
    <citation>Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B, Hamilton J, Ming JE, Radin A, Stahl N, Yancopoulos GD, Graham N, Pirozzi G. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66. doi: 10.1056/NEJMoa1304048. Epub 2013 May 21.</citation>
    <PMID>23688323</PMID>
  </reference>
  <reference>
    <citation>Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, Eckert L, Graham NM, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016 Jul 2;388(10039):31-44. doi: 10.1016/S0140-6736(16)30307-5. Epub 2016 Apr 27.</citation>
    <PMID>27130691</PMID>
  </reference>
  <reference>
    <citation>Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item Sinonasal Outcome Test. Clin Otolaryngol. 2009 Oct;34(5):447-54. doi: 10.1111/j.1749-4486.2009.01995.x.</citation>
    <PMID>19793277</PMID>
  </reference>
  <reference>
    <citation>Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav. 1984 Mar;32(3):489-502.</citation>
    <PMID>6463130</PMID>
  </reference>
  <reference>
    <citation>Lund VJ, Kennedy DW. Staging for rhinosinusitis. Otolaryngol Head Neck Surg. 1997 Sep;117(3 Pt 2):S35-40. Review.</citation>
    <PMID>9334786</PMID>
  </reference>
  <reference>
    <citation>Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004 Jan;113(1):59-65.</citation>
    <PMID>14713908</PMID>
  </reference>
  <reference>
    <citation>Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest. 1999 May;115(5):1265-70.</citation>
    <PMID>10334138</PMID>
  </reference>
  <reference>
    <citation>Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38.</citation>
    <PMID>16055882</PMID>
  </reference>
  <reference>
    <citation>Gillett S, Hopkins C, Slack R, Browne JP. A pilot study of the SNOT 22 score in adults with no sinonasal disease. Clin Otolaryngol. 2009 Oct;34(5):467-9. doi: 10.1111/j.1749-4486.2009.01975.x.</citation>
    <PMID>19793280</PMID>
  </reference>
  <reference>
    <citation>Lange B, Thilsing T, Baelum J, Kjeldsen AD. The Sinonasal Outcome Test 22 score in persons without chronic rhinosinusitis. Clin Otolaryngol. 2016 Apr;41(2):127-30. doi: 10.1111/coa.12481. Epub 2016 Feb 4.</citation>
    <PMID>26095903</PMID>
  </reference>
  <reference>
    <citation>Sommer DD, Hoffbauer S, Au M, Sowerby LJ, Gupta MK, Nayan S. Treatment of aspirin exacerbated respiratory disease with a low salicylate diet: a pilot crossover study. Otolaryngol Head Neck Surg. 2015 Jan;152(1):42-7. doi: 10.1177/0194599814555836. Epub 2014 Oct 24. Erratum in: Otolaryngol Head Neck Surg. 2015 Feb;152(2):378.</citation>
    <PMID>25344589</PMID>
  </reference>
  <reference>
    <citation>Sommer DD, Rotenberg BW, Sowerby LJ, Lee JM, Janjua A, Witterick IJ, Monteiro E, Gupta MK, Au M, Nayan S. A novel treatment adjunct for aspirin exacerbated respiratory disease: the low-salicylate diet: a multicenter randomized control crossover trial. Int Forum Allergy Rhinol. 2016 Apr;6(4):385-91. doi: 10.1002/alr.21678. Epub 2016 Jan 11.</citation>
    <PMID>26751262</PMID>
  </reference>
  <reference>
    <citation>Cho KS, Soudry E, Psaltis AJ, Nadeau KC, McGhee SA, Nayak JV, Hwang PH. Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease. Otolaryngol Head Neck Surg. 2014 Oct;151(4):575-81. doi: 10.1177/0194599814545750. Epub 2014 Aug 12.</citation>
    <PMID>25118195</PMID>
  </reference>
  <reference>
    <citation>Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, Hellings P, Jiao L, Wang L, Evans RR, Pirozzi G, Graham NM, Swanson B, Hamilton JD, Radin A, Gandhi NA, Stahl N, Yancopoulos GD, Sutherland ER. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. JAMA. 2016 Feb 2;315(5):469-79. doi: 10.1001/jama.2015.19330.</citation>
    <PMID>26836729</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 29, 2018</study_first_submitted>
  <study_first_submitted_qc>July 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2018</study_first_posted>
  <last_update_submitted>July 31, 2019</last_update_submitted>
  <last_update_submitted_qc>July 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rochester General Hospital</investigator_affiliation>
    <investigator_full_name>S. Shahzad Mustafa</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

